Skip to content

Triamcinolone and Verapamil injection on Keloid scars

Evaluation of the combined effect of intralesional injection of Triamcinolone and Verapamil in the treatment of post-surgery Keloid scars

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20210524051384N6
Enrollment
16
Registered
2021-11-14
Start date
2021-11-22
Completion date
Unknown
Last updated
2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgical keloid lesion. Hypertrophic scar

Interventions

Intervention 1: Intervention group: patients which are candidate of receiving triamcinolone (without verapamil), Injections into scars with Insulin gauge syringe No. 24 without local anesthesia and in

Sponsors

Rasht University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: The Keloid scar should be at least 0.5 cm long and at most 10 cm At least 3 months will be passed since their surgery Patients are in the age range of 18 to 50 years consent Informed

Exclusion criteria

Exclusion criteria: Keloid scars with a duration of more than 12 months Patients with infection or any other disease in the vicinity of the wound Pregnant patients or those who plan to become pregnant in the near future Breastfeeding women Diabetic patients Patients with high blood pressure or heart problems People with chronic kidney disease or those who have had any abnormal changes in the CBC or liver tests Patients taking steroids or verapamil for other conditions Keloid scars of the head, face and neck

Design outcomes

Primary

MeasureTime frame
Length, Width, height of Keloid. Timepoint: Upon arrival and after each injection session until the lesion is completely flattened or up to 8 sessions. Method of measurement: Observer measurement by calibrated compass.;Redness of the lesion. Timepoint: Upon arrival and after each injection session until the lesion is completely flattened or up to 8 sessions. Method of measurement: Based on the description of the Oscar method.;Pigmentation. Timepoint: Upon arrival and after each injection session until the lesion is completely flattened or up to 8 sessions. Method of measurement: Based on the description of the Oscar method.;Flexibility. Timepoint: Upon arrival and after each injection session until the lesion is completely flattened or up to 8 sessions. Method of measurement: Based on the description of the Oscar method.;Severe itching. Timepoint: Upon arrival and after each injection session until the lesion is completely flattened or up to 8 sessions. Method of measurement: Based on the description of the Oscar method.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Ramin Hadadi

Rasht University of Medical Sciences

raminhadadi69@yahoo.com+98 13 3336 8540

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026